▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #376 by analyst upside · 2026-11-13
WVE
Wave Life Sciences, Inc.
Healthcare · Market Cap $622M · P/E 0x
ANALYST PRICE TARGET
+427.1%
implied upside to consensus target
Current Price $3.15
Consensus Target $16.63
Bull Target $44.0
Bear Target $10.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
15
Hold
2
Sell
0
52-Week Low $3.04
52-Week High $21.73
YTD Return -80.2%
FUNDAMENTALS
Market Cap $622M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.07
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $71M
Profit Margin -296.9%
52-WEEK RANGE
52-Week Low $3.04
52-Week High $21.73
Current Price $3.15
Bear Target $10.0
Bull Target $44.0
● Now $3.15 ● Target $16.63
TRADING DATA
Avg Volume 3.2M
YTD Return -80.2%
Analyst Count 19
Consensus Buy
Upside to Target +427.1%
Last Updated 2026-11-13

ANALYST SUMMARY

Wave Life Sciences, Inc. (WVE) is currently trading at $3.15 with a Wall Street consensus price target of $16.63, implying potential upside of 427.1% over the next 12 months. 19 analysts currently cover WVE, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $44.0, while the most cautious has a target of $10.0.

WVE operates in the Healthcare sector with a market capitalisation of $622M. The stock is down 80.2% year-to-date and is currently trading near the lower end of its 52-week range of $3.04 – $21.73.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for WVE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-10-29 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-10-28 14% win rate (7 calls)
William Blair ● Initiated
Outperform 2026-10-16 44% win rate (9 calls)
UBS ● Initiated
Buy 2026-10-15 33% win rate (6 calls)
Ladenburg Thalmann ● Initiated
Buy 2026-10-01 25% win rate (8 calls)
JP Morgan ↓ Downgrade
Overweight → Neutral 2026-09-23 43% win rate (7 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-08-04 Building track record
Citigroup - Reiterated
Buy → Buy 2026-07-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →